Skip to main content
Erschienen in: Quality of Life Research 11/2017

20.06.2017

Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

verfasst von: Jacobien M. Kieffer, Tjeerd J. Postma, Lonneke van de Poll-Franse, Floortje Mols, Jan J. Heimans, Guido Cavaletti, Neil K. Aaronson, In Collaboration with the CI-PeriNomS Group

Erschienen in: Quality of Life Research | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20).

Methods

Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified.

Results

CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy.

Conclusions

Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Riaz, S. S., & Tomlinson, D. R. (1996). Neurotrophic factors in peripheral neuropathies: Pharmacological strategies. Progress in Neurobiology, 49(2), 125–143.CrossRefPubMed Riaz, S. S., & Tomlinson, D. R. (1996). Neurotrophic factors in peripheral neuropathies: Pharmacological strategies. Progress in Neurobiology, 49(2), 125–143.CrossRefPubMed
2.
Zurück zum Zitat Miltenburg, N. C., & Boogerd, W. (2014). Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Reviews, 40(7), 872–882.CrossRefPubMed Miltenburg, N. C., & Boogerd, W. (2014). Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Reviews, 40(7), 872–882.CrossRefPubMed
3.
Zurück zum Zitat Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology, 14(Suppl 4), iv45–iv54.CrossRefPubMedPubMedCentral Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology, 14(Suppl 4), iv45–iv54.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707.CrossRefPubMed Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707.CrossRefPubMed
5.
Zurück zum Zitat Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22(8), 2261–2269.CrossRefPubMed Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22(8), 2261–2269.CrossRefPubMed
6.
Zurück zum Zitat Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13(3), 176–181.CrossRefPubMed Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13(3), 176–181.CrossRefPubMed
7.
Zurück zum Zitat Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total neuropathy score: Validation and reliability study. Neurology, 53(8), 1660–1664.CrossRefPubMed Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total neuropathy score: Validation and reliability study. Neurology, 53(8), 1660–1664.CrossRefPubMed
8.
Zurück zum Zitat Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. (2010). Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 46(3), 479–494.CrossRefPubMed Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. (2010). Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 46(3), 479–494.CrossRefPubMed
9.
Zurück zum Zitat Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol, 7(11), 903–909.CrossRefPubMed Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol, 7(11), 903–909.CrossRefPubMed
10.
Zurück zum Zitat Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., et al. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 25(1), 257–264.CrossRefPubMed Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., et al. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 25(1), 257–264.CrossRefPubMed
11.
Zurück zum Zitat Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32(18), 1941–1967.CrossRefPubMed Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32(18), 1941–1967.CrossRefPubMed
12.
Zurück zum Zitat Hausheer, F., Schilsky, R., Bain, S., Berghorn, E., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15–49.CrossRefPubMed Hausheer, F., Schilsky, R., Bain, S., Berghorn, E., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15–49.CrossRefPubMed
13.
Zurück zum Zitat Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC. Support Care Center, 17(12), 1483–1491.CrossRef Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC. Support Care Center, 17(12), 1483–1491.CrossRef
14.
Zurück zum Zitat Land, S., Kopec, J., Cecchini, R., Ganz, P., Wieand, H. S., Colangelo, L., et al. (2007). Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology, 25(16), 2205–2211.CrossRefPubMed Land, S., Kopec, J., Cecchini, R., Ganz, P., Wieand, H. S., Colangelo, L., et al. (2007). Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology, 25(16), 2205–2211.CrossRefPubMed
15.
Zurück zum Zitat Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. (2003). Measuring the side effects of taxane therapy in oncology. Cancer, 98(4), 822–831.CrossRefPubMed Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. (2003). Measuring the side effects of taxane therapy in oncology. Cancer, 98(4), 822–831.CrossRefPubMed
16.
Zurück zum Zitat Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of supportive oncology, 4, W1–W8. Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of supportive oncology, 4, W1–W8.
17.
Zurück zum Zitat Driessen, C. M. L., Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., & Vreugdenhil, G. (2012). Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients. Supportive Care in Cancer, 20(4), 877–881.CrossRefPubMed Driessen, C. M. L., Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., & Vreugdenhil, G. (2012). Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients. Supportive Care in Cancer, 20(4), 877–881.CrossRefPubMed
18.
Zurück zum Zitat Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139.CrossRefPubMed Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139.CrossRefPubMed
19.
Zurück zum Zitat Sprangers, M. A. G., Cull, A., Groenvold, M., Bjordal, K., Blazeby, J., & Aaronson, N. K. (1998). The European organization for research and treatment of cancer approach to developing questionnaire modules: An update and overview. Quality of Life Research, 7(4), 291–300.CrossRefPubMed Sprangers, M. A. G., Cull, A., Groenvold, M., Bjordal, K., Blazeby, J., & Aaronson, N. K. (1998). The European organization for research and treatment of cancer approach to developing questionnaire modules: An update and overview. Quality of Life Research, 7(4), 291–300.CrossRefPubMed
20.
Zurück zum Zitat Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297–1300.CrossRefPubMed Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297–1300.CrossRefPubMed
21.
Zurück zum Zitat Wolf, S., Barton, D., Qin, R., Wos, E., Sloan, J., Liu, H., et al. (2012). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Supportive Care in Cancer, 20(3), 625–632.CrossRefPubMed Wolf, S., Barton, D., Qin, R., Wos, E., Sloan, J., Liu, H., et al. (2012). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Supportive Care in Cancer, 20(3), 625–632.CrossRefPubMed
22.
Zurück zum Zitat Lavoie Smith, E., Barton, D., Qin, R., Steen, P., Aaronson, N., & Loprinzi, C. (2013). Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Quality of Life Research, 22(10), 2787–2799.CrossRefPubMedPubMedCentral Lavoie Smith, E., Barton, D., Qin, R., Steen, P., Aaronson, N., & Loprinzi, C. (2013). Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Quality of Life Research, 22(10), 2787–2799.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., et al. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454–462.CrossRefPubMed Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., et al. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454–462.CrossRefPubMed
24.
Zurück zum Zitat Hausheer, F. H., Kanter, P., Cao, S., Haridas, K., Seetharamulu, P., Reddy, D., et al. (1998). Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Seminars in Oncology, 25(5), 584–599.PubMed Hausheer, F. H., Kanter, P., Cao, S., Haridas, K., Seetharamulu, P., Reddy, D., et al. (1998). Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Seminars in Oncology, 25(5), 584–599.PubMed
25.
Zurück zum Zitat Reilly, R. T. (2004). BNP-7787 (BioNumerik/Baxter Oncology/Grelan). IDrugs, 7(1), 64–69.PubMed Reilly, R. T. (2004). BNP-7787 (BioNumerik/Baxter Oncology/Grelan). IDrugs, 7(1), 64–69.PubMed
26.
Zurück zum Zitat Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., et al. (2000). Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. International Journal of Radiation Oncology * Biology *Physics, 47(1), 13–47.CrossRef Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., et al. (2000). Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. International Journal of Radiation Oncology * Biology *Physics, 47(1), 13–47.CrossRef
27.
Zurück zum Zitat Muthén, L. K., & Muthén, B. O. (1998–2010). Mplus User’s Guide (6th ed.). Los Angeles, CA: Muthén & Muthén. Muthén, L. K., & Muthén, B. O. (1998–2010). Mplus User’s Guide (6th ed.). Los Angeles, CA: Muthén & Muthén.
29.
Zurück zum Zitat Flora, D., & Curran, P. (2004). An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychological Methods, 9(4), 466.CrossRefPubMedPubMedCentral Flora, D., & Curran, P. (2004). An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychological Methods, 9(4), 466.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Reise, S. P., Morizot, J., & Hays, R. D. (2007). The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Quality of Life Research, 16(Suppl 1), 19–31.CrossRefPubMed Reise, S. P., Morizot, J., & Hays, R. D. (2007). The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Quality of Life Research, 16(Suppl 1), 19–31.CrossRefPubMed
31.
Zurück zum Zitat Reise, S. P., Moore, T. M., & Haviland, M. G. (2010). Bifactor models and rotations: Exploring the extent to which multidimensional data yield univocal scale scores. Journal of Personality Assessment, 92(6), 544–559.CrossRefPubMedPubMedCentral Reise, S. P., Moore, T. M., & Haviland, M. G. (2010). Bifactor models and rotations: Exploring the extent to which multidimensional data yield univocal scale scores. Journal of Personality Assessment, 92(6), 544–559.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Schermelleh-Engel, K., Moosbrugger, H., & Muller, H. (2003). Evaluating the fit of structural equation models: Tests of significance and descriptive goodness-of-fit measures. Methods of Psychological Research-Online, 8, 23–74. Schermelleh-Engel, K., Moosbrugger, H., & Muller, H. (2003). Evaluating the fit of structural equation models: Tests of significance and descriptive goodness-of-fit measures. Methods of Psychological Research-Online, 8, 23–74.
33.
Zurück zum Zitat Ferguson, E., & Cox, T. (1993). Exploratory factor analysis: A users’guide. International Journal of Selection and Assessment, 1(2), 84–94.CrossRef Ferguson, E., & Cox, T. (1993). Exploratory factor analysis: A users’guide. International Journal of Selection and Assessment, 1(2), 84–94.CrossRef
34.
Zurück zum Zitat Cattell, R. B., & Vogelmann, S. (1977). A comprehensive trial of the scree and kg criteria for determining the number of factors. Multivariate Behavioral Research, 12(3), 289–325.CrossRefPubMed Cattell, R. B., & Vogelmann, S. (1977). A comprehensive trial of the scree and kg criteria for determining the number of factors. Multivariate Behavioral Research, 12(3), 289–325.CrossRefPubMed
35.
Zurück zum Zitat Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group and of the Quality of Life Unit. (2001). EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussels EORTC. Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group and of the Quality of Life Unit. (2001). EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussels EORTC.
36.
Zurück zum Zitat Šidák, Z. (1967). Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62(318), 626–633. Šidák, Z. (1967). Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62(318), 626–633.
37.
Zurück zum Zitat Cersosimo, R. (2005). Oxaliplatin-associated neuropathy: A review. The Annals of Pharmacotherapy, 39(1), 128–135.CrossRefPubMed Cersosimo, R. (2005). Oxaliplatin-associated neuropathy: A review. The Annals of Pharmacotherapy, 39(1), 128–135.CrossRefPubMed
38.
Zurück zum Zitat Cohen, J. (1977). Statistical power analysis for the behavioural sciences (revised ed.). New York: Academic Press Cohen, J. (1977). Statistical power analysis for the behavioural sciences (revised ed.). New York: Academic Press
39.
Zurück zum Zitat Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.PubMed Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.PubMed
40.
Zurück zum Zitat Egan, M., Burke, E., Meskell, P., MacNeela, P., & Dowling, M. (2015). Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. Journal of Research in Nursing. doi:10.1177/1744987115574296. Egan, M., Burke, E., Meskell, P., MacNeela, P., & Dowling, M. (2015). Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. Journal of Research in Nursing. doi:10.​1177/​1744987115574296​.
41.
Zurück zum Zitat Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., et al. (2014). Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 32(10), 997–1005.CrossRefPubMed Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., et al. (2014). Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 32(10), 997–1005.CrossRefPubMed
42.
Zurück zum Zitat Fayers, P., & Hand, D. (2002). Causal variables, indicator variables and measurement scales: An example from quality of life. Journal of the Royal Statistical Society: Series A (Statistics in Society), 165(2), 233–253.CrossRef Fayers, P., & Hand, D. (2002). Causal variables, indicator variables and measurement scales: An example from quality of life. Journal of the Royal Statistical Society: Series A (Statistics in Society), 165(2), 233–253.CrossRef
43.
Zurück zum Zitat Kieffer, J., Verrips, E., & Hoogstraten, J. (2009). Model specification in oral health-related quality of life research. European Journal of Oral Sciences, 117(5), 481–484.CrossRefPubMed Kieffer, J., Verrips, E., & Hoogstraten, J. (2009). Model specification in oral health-related quality of life research. European Journal of Oral Sciences, 117(5), 481–484.CrossRefPubMed
44.
Zurück zum Zitat Fayers, P. M., & Hand, D. J. (1997). Factor analysis, causal indicators and quality of life. Quality of Life Research, 6(2), 139–150.CrossRefPubMed Fayers, P. M., & Hand, D. J. (1997). Factor analysis, causal indicators and quality of life. Quality of Life Research, 6(2), 139–150.CrossRefPubMed
45.
Zurück zum Zitat Sprangers, M. A. G., te Velde, A., & Aaronson, N. K. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer, 35(2), 238–247.CrossRefPubMed Sprangers, M. A. G., te Velde, A., & Aaronson, N. K. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer, 35(2), 238–247.CrossRefPubMed
46.
Zurück zum Zitat Fayers, P. M., Hand, D. J., Bjordal, K., & Groenvold, M. (1997). Causal indicators in quality of life research. Quality of Life Research, 6(5), 393–406.CrossRefPubMed Fayers, P. M., Hand, D. J., Bjordal, K., & Groenvold, M. (1997). Causal indicators in quality of life research. Quality of Life Research, 6(5), 393–406.CrossRefPubMed
47.
Zurück zum Zitat Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et al. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. Journal of Clinical Oncology, 22(4), 714–724.CrossRefPubMed Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et al. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. Journal of Clinical Oncology, 22(4), 714–724.CrossRefPubMed
48.
Zurück zum Zitat Hilarius, D. L., Kloeg, P. H., Gundy, C. M., & Aaronson, N. K. (2008). Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: A community hospital-based intervention study. Cancer, 113(3), 628–637.CrossRefPubMed Hilarius, D. L., Kloeg, P. H., Gundy, C. M., & Aaronson, N. K. (2008). Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: A community hospital-based intervention study. Cancer, 113(3), 628–637.CrossRefPubMed
49.
Zurück zum Zitat Ruland, C. M., Holte, H. H., Røislien, J., Heaven, C., Hamilton, G. A., Kristiansen, J., et al. (2010). Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. Journal of the American Medical Informatics Association, 17(4), 403–410.CrossRefPubMedPubMedCentral Ruland, C. M., Holte, H. H., Røislien, J., Heaven, C., Hamilton, G. A., Kristiansen, J., et al. (2010). Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. Journal of the American Medical Informatics Association, 17(4), 403–410.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Kluetz, P. G., Slagle, A., Papadopoulos, E., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research, 22(7), 1553–1558.CrossRefPubMed Kluetz, P. G., Slagle, A., Papadopoulos, E., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research, 22(7), 1553–1558.CrossRefPubMed
Metadaten
Titel
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)
verfasst von
Jacobien M. Kieffer
Tjeerd J. Postma
Lonneke van de Poll-Franse
Floortje Mols
Jan J. Heimans
Guido Cavaletti
Neil K. Aaronson
In Collaboration with the CI-PeriNomS Group
Publikationsdatum
20.06.2017
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 11/2017
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1626-1

Weitere Artikel der Ausgabe 11/2017

Quality of Life Research 11/2017 Zur Ausgabe